Search
Searching Goglides
Loading matching companies, research, topics, and discussions.
Loading matching companies, research, topics, and discussions.
Search uses Goglides API results from the projection-backed discovery index. Private, draft, hidden, unpublished, and admin-only content stays out of public results.
Showing public results only.
Caterpillar reported FY2025 revenue of $67.6 billion, FY2025 operating income of $11.2 billion and Q1 2026 revenue of $17.4 billion. The thesis is dealer-network strength, margin durability and cash generation through an industrial cycle.
Tag facets appear after tag usage counts are rebuilt.
QuantumScape reported no revenue in FY2025 or Q1 2026, a FY2025 net loss of $435.1 million and Q1 2026 operating cash use of $59.5 million. The thesis depends on technology milestones, partner validation, manufacturing scale-up, cash runway and dilution contro
OpenPfizer reported FY2025 revenue of $62.6 billion and Q1 2026 revenue of $14.5 billion. The thesis depends on portfolio durability, oncology integration, patent cliffs, operating cash flow, debt capacity and pipeline execution.
OpenHims & Hers expanded its subscriber benefits bundle to ten partner brands. The update is not a direct revenue story yet; it is a retention, churn, and marketing-efficiency proof test.
OpenHIMS Q1 met the revenue test and raised revenue guidance, but lower margins and reduced adjusted EBITDA guidance keep the thesis conditional.
OpenHims & Hers opened a Canada generic semaglutide path and closed $402.5M of zero-coupon convertible debt. The update turns HIMS into a global expansion versus dilution proof test.
OpenGE Vernova reported FY2025 revenue of $38.1 billion, FY2025 operating income of $1.4 billion, FY2025 operating cash flow of $5.0 billion and Q1 2026 revenue of $9.3 billion. The setup depends on grid demand, power-equipment execution, contract liabilities, mar
OpenDeere reported FY2025 revenue of $45.7 billion and Q1 2026 revenue of $9.6 billion. The thesis depends on farm-cycle demand, precision technology, dealer discipline, margins and financing credit quality.
OpenAgomAb Therapeutics is a newly public clinical-stage fibrosis biotech with no revenue, a Nasdaq ADS listing, an IPO-funded runway into the first half of 2029, and two 2026 data tracks that need to validate organ-restricted ALK5 inhibition.
Openagilon health turned in a stronger Q1 after a brutal FY2025 reset, but the thesis still depends on whether member exits, payor discipline, ACO contribution and CEO execution can hold up against Medicare Advantage medical-cost trend.
OpenAGCO is a global farm-equipment maker with Fendt, Massey Ferguson, PTx and Valtra, but the current thesis is a cycle and execution test: FY2025 sales fell 13.5%, Q1 2026 sales rebounded 14.3%, Europe carried segment profit, and PTx precision agriculture must p
OpenFirst Majestic is producing real cash in a high silver and gold price tape. The decision point is whether costs, Mexico tax risk, resource conversion and Jerritt Canyon restart spending leave enough of that cash for shareholders.
OpenAnfield Energy's updated PEA makes the Shootaring mill restart look explosive, but AEC is still a no-revenue uranium developer that has to clear permits, capital, reserves, construction, and first production.
OpenAebi Schmidt is a newly enlarged specialty-vehicle platform with snowplows, municipal equipment, airport equipment, commercial truck bodies, Shyft merger synergies, a $1.3 billion backlog, and a leverage target that needs cash conversion.
OpenAdient has the footprint OEMs need and the revenue scale investors notice, but the stock case comes down to whether EMEA repair, Asia pricing, launch costs, tariffs, and working capital finally let margin catch up with sales.
OpenAcacia is a public acquisition/operator vehicle with energy wells, industrial printers, Deflecto manufacturing, patent licensing, life-sciences remnants, and a large capital base. The question is whether those parts compound per-share value or bury it in compl
OpenAclaris has enough cash to run a busy 2026 immunology catalyst calendar, but the company still has no approved wholly controlled product, recurring operating losses, ATM dilution, and several clinical proof gates that can change the story quickly.
OpenOfficial-source baseline for ABM Industries using SEC submissions, SEC company facts, the FY2025 Form 10-K, Q1 FY2026 Form 10-Q, filed earnings releases, the 2026 proxy, WGNSTAR disclosures, and official peer filings.
OpenOfficial-source baseline for AbbVie using SEC submissions, FY2025 10-K, Q1 FY2026 10-Q, filed Q1 2026 results, FY2025 results exhibit, proxy materials, annual meeting results, debt filings, and official peer filings.
OpenArcosa just became a cleaner infrastructure bet: fewer barges, more aggregates, and a bigger utility-structure backlog. The question is whether the simpler company can turn those tailwinds into cash instead of another capital cycle.
OpenSigned-in searches appear here after you use search.
Tag facets appear after tag usage counts are rebuilt.
Tag facets appear after tag usage counts are rebuilt.